Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Dabur Pharma Forays Into Pak Aanti-cancer Drug Market (India)

This article was originally published in PharmAsia News

Executive Summary

Dabur Pharma has made a foray into the anti-cancer drug market in Pakistan and Turkmenistan. "Increasingly, our focus is to expand not only in the developed markets but also in emerging ones. Recently we have started exporting our anti-cancer drugs to Pakistan," says Dabur Pharma Additional Director and Non-Executive Chairman Mohit Burman. The move follows the Pakistan government allowing imports of anti-cancer drugs from India, and the nation's health ministry has already granted permission to two companies, Atco Pharma and AJ Mirza Pharma to import from Dabur Pharma. Dabur Pharma has also started dispatches to Turkmenistan from its dosage form manufacturing unit at Baddi in Himachal Pradesh. Earlier this year, Dabur Pharma acquired the sales and distribution network of Thai firm Biosciences. Meanwhile, the company's drug Intaxel became the first ever generic oncology drug to cross 100 million Baht sales mark in the country. (Click here for more

You may also be interested in...

Bayer's Finerenone Hints Positive In Diabetic Kidney Disease

The Phase III FIDELIO trial of finerenone has been a success but analysts want to see some actual data before declaring it an unqualified one.

Gilead’s Comparative Analysis To Bolster Remdesivir Draws Criticism

Gilead says remdesivir improved mortality and clinical recovery in COVID-19 patients, but the findings come from a retrospective analysis, not a traditional clinical trial.

US FDA Announces Plans To Resume Domestic Inspections

Agency resuming domestic inspections with the help of a pandemic rating system to identify localities where inspections will be safest for investigators and plant workers. Another safety factor: all inspections will be pre-announced.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts